Takeda Reports FY2017 Full Year Results and Issues FY2018 Guidance

OSAKA, Japan–(BUSINESS WIRE)–May 14, 2018–Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth +5.5% led by Takeda’s Growth Drivers Underlying Revenue grew +5.5%, with Takeda’s Growth Drivers (Gastroenterology, Oncology …
( read original story …)